

1 Evaluating malaria elimination strategies in military forces in  
2 Cambodia: a cluster-randomized clinical trial comparing monthly  
3 prophylaxis with focused screening and treatment  
4

5 Mariusz Wojnarski<sup>1</sup>, Sidhartha Chaudhury<sup>1,5</sup>, Threechada Boonchan<sup>1</sup>, Rathvicheth Bun<sup>3</sup>, Soklyda Chann<sup>3</sup>, Panita  
6 Gosi<sup>1</sup>, Kin Soveasna<sup>2</sup>, Sokhun Song<sup>1</sup>, Nillawan Buathong<sup>1</sup>, Mali Ittiverakul<sup>1</sup>, Sabaithip Sriwichai<sup>1</sup>, Montri Arsanok<sup>1</sup>,  
7 Worachet Kuntawunginn<sup>1</sup>, Piyaporn Saingam<sup>1</sup>, Chaiyaporn Chaisatit<sup>1</sup>, Alongkot Ponlawat<sup>1</sup>, Thanyalak Fansiri<sup>1</sup>,  
8 Pattaraporn Vanachayangkul<sup>1</sup>, Boonsong Jaichapor<sup>1</sup>, Muth Sinoun<sup>3</sup>, Char Meng Chuor<sup>3</sup>, Thay Kheangheng<sup>3</sup>, Mary  
9 So<sup>2</sup>, Elizabeth Wanja<sup>1</sup>, Silas Davidson<sup>1</sup>, Michele Spring<sup>1</sup>, Huy Rekol<sup>3</sup>, Lek Dysoley<sup>3,7</sup>, Kong Saly<sup>2</sup>, Jeffrey R.  
10 Livezey<sup>1</sup>, Jessica T. Lin<sup>4</sup>, Philip L. Smith<sup>1,8</sup>, Prom Satharath<sup>2</sup>, Jessica E. Manning<sup>6,9</sup>, Somethy Sok<sup>1\*</sup>, David L.  
11 Saunders<sup>1,5\*</sup>

12 1. Walter Reed Army Institute of Research - Armed Forces Research Institute of Medical Sciences, Bangkok,  
13 Thailand

14 2. Ministry of National Defense, Department of Health, Phnom Penh, Cambodia

15 3. National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia

16 4. University of North Carolina School of Medicine, Chapel Hill, NC, United States

17 5. Uniformed Services University School of Medicine, Bethesda, MD, United States

18 6. International Center of Excellence in Research, National Institute of Allergy and Infectious Disease, National  
19 Institutes of Health, Phnom Penh, Cambodia and Laboratory of Malaria and Vector Research, NIH, Bethesda, MD

20 7. School of Public Health, National Institute of Public Health, Phnom Penh, Cambodia

21 8. Defense Health Agency, Falls Church, VA, United States

22 9. Sanofi-Pasteur, Bethesda, MD, United States

23 \* The Authors indicated contributed to this manuscript equally.

24 **§Corresponding author:** Sidhartha Chaudhury, [sidhartha.chaudhury.mil@health.mil](mailto:sidhartha.chaudhury.mil@health.mil)

25

26

27

28

## 29 Abstract

30

### 31 Background

32 Identifying effective malaria elimination strategies for remote forested regions in Southeast Asia is  
33 challenging given limited resources. In this study, two malaria elimination strategies were evaluated in  
34 partnership with the Royal Cambodian Armed Forces - monthly malaria prophylaxis (MMP) and focused  
35 screening and treatment (FSAT).

### 36 Methods

37 Eight primarily military clusters (1,050 volunteers total) along the Cambodian-Thai border were  
38 randomized to 3 months of MMP or FSAT with monthly malaria testing by RDT, PCR, and microscopy  
39 for six months. Clusters were sub-randomized to permethrin treated (ITU) or sham water-treated clothing  
40 (sITU). Volunteers in MMP clusters were given three full monthly dihydroartemisinin-piperaquine (DP)  
41 treatment courses with 12 weekly 22.5mg primaquine. Volunteers in FSAT clusters were treated with  
42 appropriate first-line antimalarials if malaria-positive by microscopy or PCR.

### 43 Results

44 *Pf* positivity in MMP clusters was reduced by 90% (10% at enrollment to 1% at 6 months; absolute risk  
45 reduction (ARR) 9%) at 6 months. However, 32% of *Pf* cases treated with DP as MMP at baseline  
46 recrudesced, requiring rescue treatment at 1 month with artesunate-mefloquine. *Pf* positivity in FSAT  
47 clusters declined 66% over 6 months (7.6% to 2.7%; ARR 4.9%). MMP reduced *Pv* positivity from 9% to  
48 0% at 3 months, but *Pv* rebounded to 6.7% at 6 months. FSAT failed to significantly reduce *Pv* positivity  
49 during the study. The 22.5mg weekly primaquine MMP regimen was safe, even for the 15% of volunteers  
50 with G6PD-deficiency. Those wearing ITU had additional *Pv* parasitemia reductions compared to sITU in  
51 the FSAT but not MMP groups. PCR was more sensitive than microscopy and RDT for detecting both  
52 species.

### 53 Conclusions

54 MMP was safe, and superior to FSAT to reduce *Pf* and *Pv*, suggesting greater utility to achieve malaria  
55 elimination in Cambodia. Low dose (22.5mg) weekly primaquine was a safe adjunct in this setting, even  
56 for those with G6PD-deficiency. Permethrin-treated clothing further reduced *Pv* parasitemia for FSAT but  
57 not MMP. MMP may be more easily scaled to eliminate malaria. The military may provide substantial  
58 support for regional elimination efforts.

59

## 60 Introduction

61 Intensive containment and control efforts have successfully reduced malaria prevalence in the  
62 Greater Mekong Subregion (GMS). However, multi-drug resistant (MDR) *Plasmodium falciparum* (*Pf*)  
63 remains endemic in border areas of Cambodia and Thailand, with confirmed spread to neighboring  
64 countries [1]. In Southeast Asia, declining efficacy of artemisinin combination therapies (ACT) has  
65 occurred within a few years of their introduction as first-line therapies [2-5]. Concerns that ‘untreatable’  
66 malaria may emerge, combined with relatively low burden favors an aggressive approach to elimination  
67 in the region. This has been codified in commitments by ASEAN leaders in 2018 and the World Health  
68 Organization in 2022 to a goal of regional elimination by 2025 for *Pf* and by 2030 for *Plasmodium vivax*  
69 (*Pv*) [6-8]. Unfortunately, the spread of MDR *Pf* has outpaced development of new antimalarials, limiting  
70 pharmacological approaches to elimination [9]. Malaria elimination is also particularly challenging  
71 among mobile populations with occupational exposures occurring in forested areas to include the military  
72 [10, 11]. Populations residing or working in forested border areas carry a significant MDR malaria  
73 burden in the GMS [12, 13]. There is currently no consensus on how elimination will be achieved for  
74 hard-to-reach mobile populations disproportionately affected by malaria [10, 11]. Multiple approaches  
75 have been suggested, most requiring further evaluation [14].

76 Two approaches are typically proposed for malaria elimination in this region. The first is ‘mass  
77 drug administration’ (MDA) and the second is ‘focused screening and treatment’ (FSAT) where entire  
78 communities are evaluated and positive members receive treatment. MDA involves mandatory treatment

79 ranging from focal areas of outbreak to entire endemic communities. While there have been a large  
80 number of MDA studies conducted over the past 70 years, a recent systematic review identified numerous  
81 challenges in comparing studies of varying designs. MDA studies are often complicated by a lack of well-  
82 defined objectives [15]. MDA is often thought to be the more effective approach because of lower costs,  
83 simplified logistics and better outcomes despite known limitations that includes potential added risk to  
84 those without malaria. Unless sustained, MDA has had limited effectiveness in practice among diverse  
85 settings [16].

86 Prior studies identified factors associated with MDA success. These include achieving at least  
87 80% population coverage, directly observed treatment (DOT), strong community engagement, and the use  
88 of 8-aminoquinolines, particularly in *Pv* transmission settings [17, 18]. However, increasing prevalence of  
89 MDR *Pf* may compromise MDA effectiveness, and repeated administrations may be necessary in high  
90 transmission areas [19]. Finally, the use of compulsory anti-malarial treatment courses with associated  
91 side-effects in healthy individuals raised ethical concerns for MDA in low-transmission settings. Despite  
92 documented logistical challenges to implementation [20], an FSAT approach was thought to be a more  
93 ethical though less effective alternative [21]. The FSAT and MDA approaches have not been evaluated  
94 head-to-head in Cambodia, and there have been few studies conducted in hard-to-reach mobile  
95 populations, particularly the military [22]. Despite widespread use of malaria chemoprophylaxis by  
96 Western militaries deploying to malaria endemic areas, this approach has not been systematically  
97 evaluated nor widely adopted by militaries in Southeast Asia.

98 Diagnostic challenges also influence potential approaches. Rapid diagnostic tests (RDTs) are a  
99 practical option to screen large populations but low sensitivity limits their ability to identify individuals  
100 with subclinical infections and low parasitemia in areas approaching malaria elimination [19, 23, 24].  
101 Significant numbers of asymptomatic cases may be missed in the FSAT approach unless more sensitive  
102 methods such as PCR are employed [23]. PCR offers greater sensitivity and specificity but is expensive,  
103 difficult to implement in austere locations, and does not detect the latent stages of *P. vivax* [25]. Even  
104 without PCR, the amount of laboratory support and follow-up required to perform adequate systematic

105 FSAT on even a monthly basis is significant [20]. The other key diagnostic challenge is detecting G6PD-  
106 deficiency for those being administered 8-aminoquinolines. While several new G6PD tests have been  
107 field tested in Southeast Asia, the gold standard quantitative testing remains expensive and difficult to  
108 implement in austere environments [26].

109 Operational costs and complexities for various elimination approaches are poorly quantified and  
110 may be underestimated. The optimal approach has yet to be defined but is likely to include vector control  
111 measures in addition to drug therapy. Vector control measures such as indoor residual insecticide  
112 spraying (IRS) and the use of insecticide treated nets (ITNs) have been widely employed in Cambodia.  
113 However, the efficacy of vector interventions suitable for militaries, including use of insecticide-  
114 impregnated uniforms and various forms of personal and spatial repellants, remain untested in field  
115 settings, particularly against disease endpoints in clinical trials. The contribution of insecticide resistance  
116 to effectiveness also remains unclear [27]. The potential roles of militaries, thought to be a potent force  
117 for elimination, have yet to be evaluated [28].

118 The present study aimed to answer some of the key outstanding questions outlined above to  
119 define optimal approaches to malaria elimination. The US Army Medical Component of the Armed  
120 Forces Research Institute of Medical Sciences (AFRIMS) conducted a cluster-randomized interventional  
121 malaria elimination trial in partnership with the Royal Cambodian Armed Forces (RCAF) and National  
122 Center for Parasitology Entomology and Malaria Control (CNM) in Cambodia. The study aimed to  
123 quantify the relative safety and effectiveness of two major interventional approaches to malaria  
124 elimination in this region: (1) monthly malaria prophylaxis (MMP) using 3 monthly 3-day treatment  
125 courses of dihydroartemisinin-piperaquine (DP) and a weekly low dose of 22.5mg of primaquine, and (2)  
126 focused screening and treatment (FSAT) of only those found to be either microscopy or PCR malaria  
127 positive using the current first-line antimalarials recommended for *Pf* and *Pv* respectively. The additive  
128 effects of insecticide-treated uniforms (ITU) on malaria prevalence were also assessed by comparing to  
129 sham-treated uniforms or clothing (sITU) to prevent infectious mosquito bites.

130

## 131 Materials and Methods

132 Details of the study protocol and methods have been previously published [29]. The overarching  
133 goal of this pilot elimination study was to increase Cambodian malaria control program capabilities to  
134 diagnose, prevent, and treat malaria with a focus on at-risk military personnel. To do so, a scalable  
135 military malaria elimination ‘unit of action’ was established at the provincial level. The Unit primarily  
136 relied on medical personnel stationed with volunteers to monitor for disease and provide DOT. The  
137 military elimination unit was staffed by 187 RCAF personnel trained and supplied by the AFRIMS-CNM  
138 research team. This team included 170 medics assigned to individual units responsible for day-to-day  
139 treatment and follow-up during the study. Medics were divided roughly evenly between clusters with  
140 centrally located administrative, laboratory and IT support staff.

141 The primary objective of the study was to compare the effectiveness of two elimination  
142 approaches. A cluster-randomized, open label interventional study was conducted in eight military  
143 residential clusters on the Cambodia-Thai border. Each cluster included approximately 120 individuals.  
144 The study aimed to determine feasibility to achieve significant reductions in malaria prevalence using a  
145 combination of available interventions. There were four clusters where reactive screening and treatment  
146 (FSAT) was employed. In FSAT clusters, malaria was confirmed by real-time PCR, with those found  
147 positive by PCR treated with currently recommended medications according to national treatment  
148 guidelines. The other four clusters received monthly malaria prophylaxis (MMP) with  
149 dihydroartemisinin-piperaquine (DP) and 12 weekly doses of low-dose primaquine (PQ) (see Study  
150 Interventions). Clusters were sub-stratified *a priori* based on low or high malaria transmission assessed  
151 through routine public health surveillance prior to the study (see Table 1). Clusters were further sub-  
152 randomized to wear of permethrin (ITU) or sham-treated (sITU) uniforms or clothing while in forested  
153 areas.

154

## 155 Study population

156 Inclusion criteria included: 1) Volunteers 18-65 years of age and their dependents  $\geq 2$  years of  
157 age, to include military and eligible Cambodian civilians eligible for care at an RCAF facility; 2) Able to  
158 give informed consent/assent; 3) Residing in the selected study areas, 4) Available for monthly follow-up  
159 for the 6-month study duration; 5) Agreed not to seek initial outside medical care for febrile illness unless  
160 referred by the study team; and 6) Authorized by the local Commander to participate in the study if on  
161 active military duty.

162 Exclusion criteria included: 1) Known allergic reaction or contraindication to interventions to be  
163 used to include dihydroartemisinin-piperaquine, artesunate-mefloquine, or primaquine; 2) Pregnant or  
164 lactating females, and females of childbearing age unwilling to use acceptable forms of contraception  
165 during the study. Study assessments took place in RCAF facilities near the Cambodia-Thai border.

166


## 167 Cluster randomization, allocation and blinding

168 The eight community clusters were randomized to either MMP or FSAT groups, using time and  
169 region-blocked randomization. This ensured that randomized clusters were geographically distinct, and  
170 that treatment (MMP vs. FSAT) and uniform conditions (ITU vs. sITU) were evenly distributed among  
171 high and low transmission areas. There were four clusters in high and four in low endemicity areas.  
172 Volunteers meeting enrollment criteria received either permethrin-treated uniforms (ITUs) or sham  
173 (water-treated) uniforms or civilian clothing as appropriate (sITUs). Clothing was treated according to  
174 cluster assignment in single-blind fashion with the volunteer, but not the investigators, blinded to  
175 assignment. Diagnostic microscopists were blinded to each other's readings and to study arm  
176 assignments. The study design is shown in Figure 1.

177

178

179



180

181

182 **Figure 1. Study design and timeline.** All volunteers were screened for malaria with monthly malaria RDT,  
183 microscopy and PCR testing. During the three-month intervention phase, volunteers in the MMP treatment arm  
184 received regularly scheduled treatment with a full monthly DP treatment course and a weekly dose of 22.5mg  
185 primaquine regardless of malaria positivity for a total dose of 270 mg. Volunteers in the FSAT arm only received  
186 treatment if found to be malaria-positive by microscopy or PCR. All volunteers in the study were screened monthly  
187 for three additional months or when symptomatic with RDT, PCR and microscopy and treated for malaria if  
188 positive. Treatment with standard-of-care medications was given if positive by microscopy or PCR within 24-48  
189 hours. Standard doses of PQ were used per national treatment guidelines in the FSAT arm.

190

## 191 Recruitment

192 Sites selected were based at military units willing to participate in the study and authorized to do  
193 so by their respective Command authorities. Authorization was granted on a collective basis to military  
194 personnel at each participating cluster prior to selection. Individuals at each site were enrolled based on  
195 willingness to participate, and authorization for military personnel by their supervisor. However, the  
196 Chain of Command was not involved in the enrollment process nor permitted to encourage or order  
197 soldiers to participate in the study. Independent civilian ombudsmen were present during consent and  
198 enrollment to minimize undue influence among participants. Study sites were stratified *a priori* into high  
199 and low malaria transmission areas based on internal RCAF malaria surveillance data from prior years.

200



## 201 Study Procedures

202           Following informed consent or parental consent with assent by minors, all subjects underwent  
203 baseline assessments including a history and physical exam, complete blood count, and malaria diagnostic  
204 testing. Glucose 6-phosphate dehydrogenase (G6PD)-deficiency screening was assessed using FDA-  
205 approved quantitative testing methods (Trinity Biotech, Ireland). Malaria diagnostics included a rapid  
206 test (SD BIOLINE Malaria Ag *Pf/Pv* malaria antigen or MALACHECK Ag pLDH/HRP2), microscopy  
207 and molecular testing with species-specific PCR using previously described methods [29]. A threshold  
208 of <35 PCR replication cycles was used to define positive results for malaria. The study consisted of a  
209 three-month intervention period with MMP or FSAT, followed by a three-month follow-up period, during  
210 which all volunteers continued monthly screening and treatment.

211           Malaria treatment was administered according to 2016 Cambodian National Treatment  
212 Guidelines (NTG). Children <13 years old were not treated with PQ and had only finger stick blood  
213 collections for malaria diagnostics. All volunteers with blood-stage parasitemia by light microscopy were  
214 followed to clinical symptom resolution with two negative blood smears at least one week apart. If  
215 volunteers were only PCR positive, they were evaluated again the following month to ensure clearance.  
216 Recurrent cases of *Pf* were evaluated with molecular genotyping of MSP-1, MSP-2, and GLURP allelic  
217 variants to distinguish recrudescence from reinfection [30].

218

## 219 Study Interventions

220           Starting at enrollment, volunteers in the MMP group received 3 monthly three-day courses of  
221 fixed-combination DP tablets (Doucotexcin, Holley Pharmaceuticals, China) containing 40 mg of DHA  
222 and 320mg of piperazine phosphate (PIP) during the intervention. All MMP volunteers age  $\geq$ 13 years  
223 also received 12 weekly PQ 22.5mg tablets (270 mg total dose) to prevent malaria transmission and *Pv*  
224 relapse. MMP participants that were found to be initially positive by PCR at enrollment received their  
225 first scheduled course of DP with the prescribed MMP regimen. However, MMP volunteers subsequently

226 found to be parasitemic by PCR or microscopy during follow-up were treated with standard-of-care  
227 antimalarials following national treatment guidelines (NTG). Volunteers in the MMP group who received  
228 rescue treatment following NTG, were treated with their regularly scheduled MMP regimen with DP on  
229 next monthly follow up, and while weekly low dose primaquine was continued on schedule without  
230 interruptions.

231         During the intervention period, all participants in FSAT clusters were screened monthly by RDT,  
232 microscopy and PCR and treated following national guidelines if positive by microscopy or PCR. All  
233 volunteers in FSAT clusters with parasitemia by PCR or microscopy were treated following the 2016  
234 Cambodia National Treatment Guidelines. *Pf*-positive volunteers and those with mixed-species infections  
235 received a full 3-day treatment course of artesunate and mefloquine (ASMQ, Guilin Pharmaceutical Co  
236 Ltd, Guilin, China) with a single low 15mg PQ dose (Government Pharmaceutical Organization,  
237 Bangkok, Thailand). *Pv*-positive volunteers received a full 3-day treatment course of DP plus 15mg PQ  
238 daily for 14 days to prevent relapse. G6PD-deficient *Pv*-positive volunteers received 8 weekly 45 mg  
239 doses of PQ. The intervention and follow-up period used the same intervention for FSAT subjects. The  
240 follow-up period for the MMP volunteers mirrored the FSAT intervention and follow-up period,  
241 reflective of the NTG. All treatment was administered as Directly Observed Therapy (DOT) by RCAF  
242 medical personnel on the study team.

243         Participants were provided with outer garments to wear in forested areas prior to study start.  
244 These included civilian clothing or military uniforms as appropriate. Garments were pre-treated with  
245 insecticide by the study team prior to distribution using a single application of 40% permethrin Individual  
246 Dynamic Absorption kits (NSN 6840-01-345-0237; U.S. Army) to produce treated clothing (ITU) or  
247 water to produce sham-treated clothing (sITU). According to the product label, permethrin treatment was  
248 designed to withstand 30 washings.

249

## 250 Statistical Analysis

251 Detailed description of the statistical plan is outlined in the prior study protocol publication [29].  
252 In brief, the primary study endpoint the absolute risk reduction (ARR) based on the proportion of  
253 volunteers in each arm with PCR-corrected absence of parasitemia at the end of 6 months using an  
254 Intention-to-Treat analysis. Power analysis to determine the minimum sample size for the study assumed  
255 a conservative value of 0.4 for the intra-class correlation coefficient (ICC). It was determined at least 78  
256 individuals were required to achieve 80% power to detect a two-fold reduction in the ARR for MDA over  
257 FSAT with an  $\alpha=0.05$ . ARR was based on the proportion of malaria-free volunteers at six months [31].  
258 As the number of available clusters was limited for practical reasons, a total of eight clusters with 80 to  
259 140 volunteers per cluster was determined to be sufficient for this pilot study.

260 Demographic, epidemiological, and laboratory data were summarized at baseline and follow-up.  
261 All enrolled volunteers were included in the database for primary endpoint analysis. The safety analysis  
262 database included all volunteers who received at least one dose of study drug. T-tests and chi-square tests  
263 were used to assess the statistical significance of differences in two means (including log-transformed) or  
264 proportions, respectively. Confidence limits (95%) for means, geometric means, and proportions were  
265 calculated. A mixed-effects logistic regression model was used to assess the role of treatment group  
266 (MMP vs. FSAT), insecticide-treated uniforms (ITU vs. sITU), cluster regional endemicity (low vs. high),  
267 and parasitemia at enrollment (positive vs. negative) on the likelihood of a *Pf* or *Pv* infection during the 6  
268 month study period. Random effects were modeled at the cluster level. Time to event data was  
269 summarized using Kaplan-Meier plots. The log-rank test was used to assess the statistical significance of  
270 differences between the treatment groups.

271

## 272 Ethics Statement

273 The trial was approved by the Walter Reed Army Institute of Research Institutional Review  
274 Board (WRAIR IRB, Protocol number, WR2211) and the National Ethics Committee for Health Research


275 (NECHR) in Cambodia. The study was registered on Clinicaltrials.gov prior to enrollment  
276 (NCT02653898).

277

## 278 Results

### 279 Enrollment and Study Follow up

280 Of the 1,114 volunteers residing in the 8 selected clusters who were screened, 1,050 enrolled into  
281 the study (**Figure 2**). This corresponded to 94.3% overall coverage in the population studied, ranging  
282 from 89-97% coverage within individual clusters. The first subject was enrolled in January 2016 and the  
283 last subject follow-up was completed in August 2016. There were 534 volunteers in four clusters assigned  
284 to MMP (264 received ITU and 270 sITU) and 516 volunteers in four clusters assigned to FSAT (240  
285 received ITU and 276 sITU). Among enrolled volunteers, 75.8 % (796/1050) were military personnel,  
286 12.8% (134/1051) were non-military adults, and 11.4% (120/1050) were children < 18 years old. All  
287 volunteers identified ethnically as Khmer, and 84.3% (885/1050) of the population were male. At six  
288 months follow up, 90.1% (485/534) in MMP and 86.0% (443/516) in FSAT groups completed all study  
289 follow-up (**Supplemental Table 1**). Overall, only 11% (124/1050) withdrew from the study before  
290 completing all procedures, generally due to geographic reassignment or to new duties which precluded  
291 continuation of follow up.



292  
 293 **Figure 2. CONSORT Flow Diagram.** Volunteers were randomized to one of 8 geographically isolated unit-based  
 294 clusters. There were a total of 4 clusters for MMP (green) and another 4 clusters for FSAT (orange) treatment  
 295 interventions. Half of the volunteers assigned to MMP and FSAT were also treated with insecticide treated uniforms  
 296 (ITUs). Total follow-up was 180 days after enrollment. Most volunteer withdrawals and losses to follow-up were  
 297 due to movement outside the study areas.

298  
 299 Cluster composition at baseline is shown in **Table 1**. The study was designed to ensure balanced  
 300 representation of all conditions (treatment, uniform, and endemicity) across the clusters within the study.  
 301 Baseline Pv prevalence was 8.4% (45/534) in the MMP groups compared to only 2.7% (13/516) in FSAT  
 302 clusters. Pf prevalence for both arms was comparable at baseline ( $Pf_{MMP} = 62/534 = 9.7\%$ ;  $Pf_{FSAT} =$   
 303  $42/516 = 8.1\%$ ). PCR-confirmed malaria prevalence at baseline was 15% (145/1050) across all clusters,  
 304 with Pf the predominant species at 8-10%. The MMP clusters had higher baseline malaria prevalence with  
 305 92 positive individuals consisting of 45 Pf cases (49%), 39 Pv cases (42%), and 8 mixed Pf/Pv infections  
 306 (9%) by PCR. Of the 53 PCR-positive cases at baseline in the FSAT clusters, there were 39 Pf cases  
 307 (73%), 13 Pv cases (25%) and 1 mixed Pf/Pv infection (2%). Withdrawals and losses to follow-up were  
 308 not evenly distributed among study groups, with a higher proportion withdrawing from the FSAT group

309 (14.5%), compared to the MMP group (9.3%). Differences were nearly 2-fold higher after month 2 with  
 310 10.5% lost or withdrawn in the FSAT groups vs. 5.6% in MMP (**Supplemental Table 1**).

311


Cluster	A	B	C	D	E	F	G	H	Total
<b>Treatment Group</b>	FSAT	MMP	MMP	FSAT	FSAT	FSAT	MMP	MMP	
<b>Uniform Assignment</b>	sITU	sITU	ITU	ITU	ITU	sITU	sITU	ITU	
<b>Baseline Endemicity</b>	High	High	High	High	Low	Low	Low	Low	
<b>Number Screened</b>	151	150	134	129	121	139	140	150	1,114
<b>Number Enrolled</b>	143 (95)	142 (95)	130 (97)	125 (97)	115 (95)	133 (96)	128 (91)	134 (89)	1,050 (94)
<b>Non-military</b>	68 (48)	61 (43)	48 (37)	43 (34)	33 (29)	0 (0)	1 (1)	0 (0)	254 (24)
Children	32 (22)	32 (23)	33 (25)	13 (10)	10 (9)	0 (0)	0 (0)	0 (0)	120 (11)
Civilian adults	36 (25)	29 (20)	15 (12)	30 (24)	23 (20)	0 (0)	1 (1)	0 (0)	134 (13)
<b>Positive for Malaria on Screening by PCR</b>	29 (20)	29 (20)	28 (21)	17 (14)	4 (3)	3 (2)	22 (17)	13 (10)	145 (14)
<i>Pf</i> infection	23 (16)	17 (13)	12 (9)	12 (10)	2 (2)	2 (1)	11 (9)	5 (4)	84 (8)
<i>Pv</i> infection	5 (3)	11 (8)	11 (8)	5 (4)	2 (2)	1 (1)	9 (7)	8 (6)	53 (5)
Mixed <i>Pf/Pv</i> infection	1 (1)	1 (1)	5 (4)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	9 (1)
<b>G6PD Deficiency WHO Class I-III</b>	15 (10)	17 (12)	25 (19)	15 (12)	13 (11)	25 (19)	23 (18)	27 (20)	160 (15)
G6PD Deficiency Primaquine-treated	5 (3)	16 (11)	25 (19)	2 (2)	2 (2)	1 (1)	22 (17)	24 (18)	97 (9.2%)
>10% Hemoglobin Drop at Day 3	0 (0)	3 (2)	6 (5)	0 (0)	1 (1)	0 (0)	3 (2)	1 (1)	14 (1.3%)

312  
 313 **Table 1. Malaria elimination cluster characteristics.** Composition of 8 geographically isolated clusters  
 314 randomized in the study including volunteer demographics, interventional assignments, baseline malaria prevalence,  
 315 G6PD-deficiency prevalence and primaquine treatments administered. Values are expressed as # (%) of those  
 316 enrolled in each cluster in rows 6 through 15. The number screened represented the population of each cluster, with  
 317 the number enrolled corresponding to intervention coverage (94% overall).  
 318

## 319 Treatment outcome by malaria species

320 All groups experienced rapid *Pf* malaria reduction within 30 days of study initiation (Fig 3A and  
321 B). At the last follow up on Day 180, less than <1% of the study population had PCR-confirmed *Pf*  
322 malaria, with *Pv* being the predominant species at 2-4% (**Figures 2, 3 and 4**). During the study period,  
323 based on the detected malaria cases, the predicted unadjusted prevalence of *P. falciparum* was 11,048  
324 episodes/100,000 population and the unadjusted prevalence of *P. vivax* was 15,238 episodes/100,000.  
325 From Month 1 to study end, 11.0% (95% CI: 8.0-11.7%) of volunteers experienced *Pv* infection and  
326 15.4% (CI: 11.5-15.7%) of volunteers experienced *Pf* infection at least once.

327 *Pf* malaria transmission was interrupted by both MMP and FSAT interventions. PCR-corrected  
328 prevalence of *Pf* malaria declined from 9.9% at baseline to 0.4% on month 6 follow up (96% decline) for  
329 MMP and from 7.6% to 0.97% (87.1% decline) in FSAT treatment group (**Figure 3, Panel A-B**). In  
330 MMP, 16 of 51 (31%) subjects that were positive for *Pf* at enrollment presented with malaria recurrence  
331 within their first two months of follow-up, with all 16 genotyped as recrudescences. All recurrent cases of  
332 *Pf* in the MMP group were successfully treated with artesunate-mefloquine at the 1-month follow-up  
333 visit. In FSAT, where all *Pf*-positive volunteers were treated with artesunate-mefloquine, 2/39 (5%) had  
334 PCR-confirmed recurrence within their first month of follow-up, and all cases were confirmed to be new  
335 infections. Volunteers assigned to the MMP arm experienced 2 cases of *Pf* in the last 3 months of follow-  
336 up, compared to 4 cases of *Pf* in FSAT arm, during the same follow-up period.



337

338 **Figure 3. PCR-adjusted malaria prevalence on the monthly follow up in MMP and FSAT.** Rapid and sustained  
 339 reductions in the number of *Pf* malaria cases were observed in MMP (green) and FSAT (orange) (Panel A-B). A  
 340 high rate of *Pv* malaria was detected for both interventions arms (Panel C-D) despite 270 mg total PQ dose in MMP  
 341 arm (G6PD normal and G6PD deficient volunteers), over a 12 week period, and conventional doses of PQ in FSAT  
 342 arm (i.e., 15 mg x 14 days in G6PD normal volunteers and 45 mg weekly x 8 weeks in G6PD deficient volunteers).  
 343 Results are stratified between subjects that were positive at enrollment and tested positive at a follow-up time point  
 344 and subjects that were negative at enrollment but tested positive at a follow-up time point. Error bars reflect the 95%  
 345 confidence interval.

346 In contrast to *Pf* infections, ongoing *Pv* infections were observed in both treatment groups after  
 347 enrollment during the study period. Despite rapid *Pv* decline in MMP, with no new cases detected during  
 348 the treatment period (Days 0-90), 45 of 481 (9.3%) MMP subjects tested positive for *Pv* parasitemia after  
 349 discontinuing prophylaxis within the 90-day follow-up period. In MMP subjects, 29% (13 of 45) of *Pv*  
 350 cases during the follow-up period were in subjects that were positive for *Pv* at enrollment (**Figure 3,**  
 351 **Panel C**). In FSAT, overall *Pv* rates were twice as high as in MMP subjects (cumulative 81 of 444,  
 352 18.2%) as in **Figure 3, Panel D**. *Pv* was more evenly distributed in the FSAT groups throughout the  
 353 study period, with an average rate of 3.0% per month. *Pv* recurrences in individuals that were *Pv* positive  
 354 at baseline made up a larger percentage of total *Pv* cases in the MMP group compared to the FSAT group  
 355 (29% vs. 4.9%). The probability of *Pv* recurrence by 6 months if *Pv*-positive at baseline was similar for



356 both groups (30% in MMP and 29% in FSAT). In contrast to MMP, only 4 of 81 *Pv* cases (4.9%)  
 357 detected during follow-up in FSAT clusters were in *Pv*-positive individuals at enrollment.

358 The primary endpoint of the study was absolute risk reduction (ARR) for malaria at 6 months. A  
 359 summary of absolute and relative risk reductions (RRR) are shown in **Table 2**. Overall there was a 68.7%  
 360 cumulative relative-risk reduction (RRR) for *Pf* malaria in MMP groups at day 90 (0.6% prevalence)  
 361 compared to FSAT (1.91%) or an absolute risk reduction (ARR) of 1.3%. RRR for *Pf* at day 180 in MMP  
 362 clusters (1.0%) was 61.5% with an ARR of 1.7% compared to FSAT (2.7%) (Table 2). Overall RRR for  
 363 *Pv* in MMP groups at day 90 (0% prevalence) was 100% compared to FSAT (9%) or an ARR of 9%.  
 364 RRR for *Pv* was 47.3% at day 180 in MMP clusters (6.7% prevalence) compared to FSAT (12.6%  
 365 prevalence) for an ARR of 6%.

366

A. Absolute (ARR) and Relative Risk Reduction (RRR) for cumulative malaria positivity for MMP vs. FSAT

<i>Pf</i>	Day 90	Day 180	<i>Pv</i>	D90	D180
FSAT	1.91%	2.70%	FSAT	9.01%	12.61%
MMP	0.60%	1.04%	MMP	0.00%	6.65%
<b>ARR</b>	<b>1.31%</b>	<b>1.66%</b>	<b>ARR</b>	<b>9.01%</b>	<b>5.96%</b>
<b>RRR</b>	<b>68.66%</b>	<b>61.54%</b>	<b>RRR</b>	<b>100.00%</b>	<b>47.25%</b>
<b>Fold-Reduction</b>	<b>3.2</b>	<b>2.6</b>	<b>Fold-Reduction</b>	<b>9</b>	<b>1.9</b>

B. Absolute (ARR) and Relative Risk Reduction (RRR) for cumulative malaria positivity for ITU compared to sITU

<i>Pf</i>	Day 90	Day 180	<i>Pv</i>	D90	D180
all.sITU	1.74%	2.93%	all.sITU	6.28%	11.09%
all.ITU	0.66%	0.67%	all.ITU	2.24%	7.83%
<b>ARR</b>	<b>1.08%</b>	<b>2.26%</b>	<b>ARR</b>	<b>4.04%</b>	<b>3.26%</b>
<b>RRR</b>	<b>62.13%</b>	<b>77.09%</b>	<b>RRR</b>	<b>64.35%</b>	<b>29.38%</b>

C. Absolute (ARR) and Relative Risk Reduction (RRR) for cumulative malaria positivity for ITU vs sITU (FSAT only)

<i>Pf</i>	Day 90	Day 180	<i>Pv</i>	D90	D180
FSAT.sITU	2.29%	3.77%	FSAT.sITU	11.45%	17.15%
FSAT.ITU	1.43%	1.46%	FSAT.ITU	4.76%	7.32%
<b>ARR</b>	<b>0.86%</b>	<b>2.30%</b>	<b>ARR</b>	<b>6.69%</b>	<b>9.84%</b>
<b>RRR</b>	<b>37.62%</b>	<b>61.14%</b>	<b>RRR</b>	<b>58.41%</b>	<b>57.35%</b>

367

368 **Table 2. Summary of absolute (ARR) and relative risk reductions (RRR) based on primary intervention**  
369 **(MMP vs FSAT) and uniform treatment (ITU vs sITU).** ARR and RRR are calculated based on cumulative  
370 PCR-confirmed malaria positivity at months 3 and 6 over the course of the study for A. MMP with respect to FSAT;  
371 B. ITU with respect to sITU for both MMP and FSAT; C. ITU compared to sITU for FSAT only.


372

373 **Figure 4.** shows gametocytes detected by microscopy for *Pf* (panel A, B) and *Pv* (panel C, D).

374 No gametocytes were seen by microscopy in MMP clusters from months 1-6 for *Pf*, or months 1-4 for *Pv*.

375 While no microscopic *Pf* gametocytes were seen from months 2-6 in the FSAT group, *Pv* gametocytes

376 persisted throughout the observation period at a low level.



377


378 **Figure 4. Microscopic gametocytemia by group for *Pf* and *Pv*.** Presence (g+) or absence (g-) of gametocytes by  
379 microscopy was assessed for each individual at each time point. At least 200 oil immersion fields were examined on  
380 a thick blood smear before it was considered negative. Panels A. and B. compare rates of microscopic  
381 gametocytemia between the FSAT and MMP groups for *Pf* gametocytes, while panels C. and D. compare rates for  
382 *Pv* gametocytes. Overall rates of infection by PCR are indicated by superimposed tan (MMP) or salmon (FSAT)  
383 colored bars.

## 384 Diagnostic Parasite Detection

385 Participants were followed with parasitemia assessed monthly by rapid diagnostic test (RDT),

386 microscopy (Micro) and plasmodium species-specific polymerase chain reaction (PCR) for 180 days.

387 Diagnostic test results are shown in **Figure 5** for the MMP and FSAT groups (**5A-B**) and *Pf* and *Pv* for  
 388 both groups (**5C-D**). Using PCR as the reference standard among 6,784 overall tests, microscopy was  
 389 highly specific for both *Pf* (99.9%) and *Pv* (100%), but far more sensitive for *Pf* (84.3%) than *Pv* (39.0%).  
 390 Microscopy was less sensitive than PCR, for both blood stage disease and gametocytes (3E-F). RDT was  
 391 also highly specific for *Pf* (99.9%) and *Pv* (100%) compared to PCR but had poor sensitivity for *Pf*  
 392 (69.4%) and virtually no sensitivity for *Pv* (0.5%).




393  
 394 **Figure 5. Diagnostic detection of malaria.** Prevalence of all malaria species at each monthly follow up is shown  
 395 based on the three diagnostic methods (RDT, microscopy, and PCR) performed on each individual at each visit.  
 396 Participants were followed with parasitemia assessed monthly by rapid diagnostic test (RDT), microscopy (Micro)  
 397 and plasmodium species-specific polymerase chain reaction (PCR) for 180 days. All RDT and Micro-positive cases  
 398 were also PCR positive. Panels A. and B. compare detection rates between the (A) FSAT and (B) MMP groups.  
 399 Panels C. and D. compare detection rates for all volunteers for (C) *P. falciparum* and (D) *P. vivax*.

#### 400 Effect of treated uniforms and endemicity on treatment outcome

401 Mixed-effects logistic regression was used to assess effects of uniform treatment and cluster  
 402 endemicity on treatment outcome. Endemicity and uniform treatments are expected to affect the rate of

403 acquiring *new* infections by affecting malaria vector exposure rates, but not rates of relapse or drug  
 404 treatment failure. As such, analysis included only subjects who were negative at enrollment for *Pf* or *Pv*,  
 405 respectively, to assess the role of treatment and endemicity without confounding from treatment failure or  
 406 relapse. Overall, for *Pf* infections, FSAT had higher cumulative *Pf* positivity at 6 months than MMP  
 407 regardless of endemicity or uniform conditions ( $p < 0.01$ ) (**Figure 6A**). Although uniform treatment had  
 408 no statistically significant effect of on cumulative *Pf* positivity, the total number of *Pf* cases in the study  
 409 after Day 30 was low (16 total cases when excluding subjects positive at enrollment). There were no cases  
 410 of *Pf* during follow-up in MMP subjects with treated uniforms. Cumulative *Pf* positivity in FSAT for  
 411 those with sham-treated uniforms (3.9%) was approximately double that of those with permethrin-treated  
 412 uniforms (1.9%; RRR 61%; ARR 2.3%).  
 413



414  
 415 **Figure 6. Cumulative *Pf* and *Pv* positivity with respect to drug intervention, uniform treatment, and**  
 416 **endemicity.** Cumulative positivity from Day 0 to 180 is shown for *Pf* (A) and *Pv* (B); MMP (green bars) and FSAT  
 417 (orange bars) treatment conditions, stratified by cluster endemicity (high vs. low) and uniform (sITU vs. ITU). 95%  
 418 confidence interval error bars and statistical significance (\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ ) are shown.

419  
 420 There were significant effects of endemicity and uniform treatment on cumulative *Pv* positivity  
 421 (**Figure 6B**). Cumulative *Pv* positivity was approximately double in clusters with high endemicity  
 422 compared to clusters with low endemicity. Stratifying for endemicity, FSAT subjects had significantly  
 423 higher *Pv* positivity than MMP subjects in high endemicity clusters ( $p < 0.05$ ) but not low endemicity


424 clusters. Stratifying by uniform type, FSAT subjects with sham-treated uniforms had almost 3-fold higher  
425 cumulative *Pv* positivity than MMP subjects with sham-treated uniforms ( $p < 0.001$ ). However, there  
426 was no difference in *Pv* positivity between MMP and FSAT subjects wearing treated uniforms. FSAT  
427 subjects wearing sham-treated uniforms had almost 2.5-fold higher *Pv* positivity at 3 (6.3%) and 6 months  
428 (17%) than FSAT subjects wearing treated uniforms (2.2% and 7.3% respectively; RRR=57.4% and  
429 ARR=9.8% at 6 months;  $p < 0.01$ ). See **Supplemental Table 2** for summary logistic regression results.

430

### 431 Malaria infection rate over time

432 Survival analysis was performed to evaluate rates of acquiring *Pf* and *Pv* infections over the  
433 course of the study. To ensure that the analysis was focused on new infections and not confounded by  
434 relapse or treatment failure, malaria positive subjects at enrollment were excluded. Time-to-event  
435 analysis was based on time to acquire the first documented *Pf* or *Pv* infection for each subject. The  
436 analysis was stratified by endemicity, and included only high endemicity clusters for *Pf* as no new *Pf*  
437 infections were observed in low endemicity clusters. *Pv* survival curves were stratified by uniform  
438 assignment (sITU vs ITU) after logistic regression analysis showed endemicity and uniform were  
439 significantly associated with cumulative *Pv* positivity.

440



441

442 **Figure 7. Survival curve to first *Pf* or *Pv* infection stratified by treatment.** Survival curves are shown for *Pf*  
443 infection for FSAT (red) and MMP (blue) treatment conditions for in high endemicity clusters (A). Survival curves  
444 for *Pv* infection in high and low endemicity clusters (B and C) are shown for FSAT+ITU (red), FSAT+sITU (green),  
445 MMP+ITU (blue), and MMP+sITU (purple) conditions. 95% confidence intervals are shown as shaded colors  
446 corresponding to each condition. There was only 1 low endemicity *Pf* case which is not graphically displayed.  
447

448 Survival analysis showed significantly fewer *Pf* infections in the MMP than FSAT groups  
449 (**Figure 7A**,  $p < 0.05$ ), with no significant differences seen based on uniform treatment (not shown). For  
450 the *Pv* survival curve in the high endemicity cluster, MMP treatment had significantly lower infection  
451 rates than FSAT treatment ( $p < 10^{-5}$ ). Treated uniforms showed significantly lower infection rates than  
452 untreated uniforms ( $p < 0.05$ ), with an interaction observed between treatment and uniform type ( $p < 0.05$ ).  
453 Overall, in the high endemicity conditions, the FSAT+sITU condition performed significantly worse than  
454 the other three conditions ( $p < 10^{-7}$ ). The *Pv* survival curve in low endemicity clusters showed no  
455 statistically significant difference in infection rates for treatment or uniform type. However, there was a  
456 trend with higher infection rates for the FSAT+sITU condition than the other three. It is important to note,  
457 in the *Pv* survival curves, that while FSAT infection rates remained steady, the MMP infection rate was  
458 zero until D90, after which it increased to a level comparable to FSAT.

459

## 460 Safety

461 Of 1,050 volunteers enrolled, there were 1,237 adverse events (AEs) reported over the 6-month study  
462 or 1.2 AEs per volunteer. The vast majority of AEs (88.0%) were classified as unlikely or not related to  
463 study interventions. The most frequent AE was upper respiratory infection. Most AEs were mild to  
464 moderate in severity, and all resolved prior to study discharge. Study drugs were well tolerated, and there  
465 were no AEs reported from ITU wear. There were 27 SAEs recorded during the study period. All were  
466 unrelated to the study interventions except for three that were classified as ‘unlikely related’ and 1  
467 ‘possibly’ related (new onset migraine headache which resulted in inpatient treatment). All volunteers  
468 with SAEs were followed until recovery or until their condition has stabilized. One volunteer was  
469 diagnosed with breast cancer and was withdrawn from the study while receiving treatment. One

470 volunteer was withdrawn due to intolerance to DHA-PIP in MMP arm (vomiting). One volunteer died  
471 from causes unrelated to study interventions with causality assessed by the research monitor, an  
472 independent review, and the ethics review board.

473 While there have been reports of clinically significant hemolysis observed following PQ  
474 treatment even in G6PD normal individuals [32], no significant hemolysis occurred in G6PD-deficient  
475 volunteers taking primaquine during the study. All volunteers with moderate to severe G6PD deficiency  
476 tolerated the modified 12 weekly doses of PQ without clinically significant hemolysis. There were 160  
477 volunteers (15%) with G6PD-deficiency identified at screening. Of these, 97 (9.2%) took primaquine  
478 during the study, but only 14 (1.3%) had a hemoglobin decline >10% at day 3 (**Table 1**). No volunteers  
479 had a hemoglobin drop >25% from baseline or required stopping therapy.

## 480 Discussion

481 At the time the study was designed in 2012, two alternative approaches to malaria elimination were  
482 debated in Cambodia. The first, often termed Mass Drug Administration or MDA was thought to be the  
483 more effective approach. MDA offers the promise of lower costs, simplified logistics and improved  
484 outcomes from sustained pressure on the parasite. However, perceptions surrounding compulsory drug  
485 treatment for apparently healthy individuals with unclear risks with low malaria transmission in the GMS  
486 raised ethical concerns. A large number of MDA studies have been conducted over the past 70 years with  
487 tremendous variation in disease settings and approaches employed. A recent systematic review  
488 highlighted difficulties comparing studies of varying designs, often complicated by a lack of well-defined  
489 objectives [15]. Despite documented logistical challenges to implementation and lower effectiveness  
490 [20], a reactive ‘screen and treat’ approach (which we termed Focused Screening and Treatment or  
491 FSAT) was thought more ethically palatable with only confirmed infections given drug treatment.  
492 Compared to prior studies that largely relied on less sensitive RDTs or microscopy, treatment in FSAT  
493 group in this study was based on PCR results affording greater number of subjects getting treatment.



494 We sought to reconcile and recast these opposing views to malaria elimination, noting that human  
495 malaria often survives in the host undetected in latent, sub-clinical and sub-microscopic forms. Further,  
496 in mixed-species transmission settings such as this one, treatment with blood stage antimalarials may not  
497 interrupt disease transmissibility, and may in fact potentiate it [33]. Our use of the term monthly malaria  
498 prophylaxis (MMP) was deliberate and intended to convey the full therapeutic intent. The MMP  
499 addresses the four facets of affective treatment and malaria prevention, namely it (1) targets blood stage  
500 infections; (2) reduces transmission risk posed by untreated infection; (3) lowers potential relapse from *Pv*  
501 if treatment is co-administered with primaquine; and (4) lowers the risk of reinfection by reduction of  
502 malaria burden. The treatments employed were intended to reduce and ultimately interrupt malaria  
503 transmission with limited need for micromanagement required with a screening and treatment approach.  
504 Namely frequent and repeated clinical evaluation, safety and molecular malaria diagnostic tests, and  
505 therapeutic interventions. Insecticide-treated clothing was assessed for added benefit against day-biting  
506 mosquitoes in endemic forested areas.

507 In the MMP regimen, the four therapeutic objectives above were achieved using  
508 dihydroartemisinin-piperaquine to treat acute parasitemia and provide suppressive chemoprophylaxis  
509 (Objectives 1 and 4), and low-dose weekly primaquine to reduce transmission risk, eliminate or suppress  
510 latent *Pv* infection (Objective 3), and provide causal liver-stage chemoprophylaxis (Objectives 2, 3, and  
511 4). MMP groups reached zero PCR-detectable malaria parasitemia after 3 months of treatment. There  
512 was no microscopic gametocytemia detected between Months 2-6 or blood-stage *Pv* by PCR between  
513 Months 2-4. There were relative risk reductions (RRR) of 60-70% in cumulative *Pf* infection in the  
514 MMP group compared to FSAT over the course of the study, with a 1.6% absolute risk reduction (ARR).  
515 The RRR of MMP relative to FSAT was 100% for *Pv* after the three-month intervention period, and 47%  
516 through 6 months of follow-up with an ARR of 6%. Uptake of therapy was excellent, well-tolerated, and  
517 coverage was high in this voluntary study. The primary drawback for MMP use was high baseline *Pf*  
518 resistance to DP in Cambodia. The ~30% clinical failures required rescue therapy with A+M at Month 1,  
519 though all were cured and remained *Pf* negative thereafter. Future studies could investigate the use of



520 other drug combinations that are more effective for MDR *Pf* strains in Cambodia which would eliminate  
521 the need for rescue treatments and monitoring for recrudescence.

522 In retrospect, the MMP results could have been achieved in this endemic community with less  
523 frequent monitoring than a reactive screen-and-treat approach. MMP findings were in contrast to those  
524 among the FSAT groups, particularly for *Pv*. The *Pv* parasitemia in MMP remained endemic at a rate of  
525 2-4% throughout the study. This was despite a 4-fold lower baseline *Pv* infection rate in FSAT clusters  
526 (~2%) compared to MMP (>8%). During the follow-up period when MMP and FSAT groups had the  
527 same screening/treatment regimen, malaria re-emerged in the MMP group, with *Pv* parasitemia detected  
528 within one month and *Pf* within three months after the intervention period. Although the study was not  
529 powered to assess the effectiveness of insecticide-treated clothing, there was a statistically significant  
530 benefit against *Pv* infection in the FSAT but not MMP groups. Uniform treatment may provide additional  
531 protection from malaria absent chemoprophylaxis as part of a screen-and-treat approach.

532 PCR was the definitive diagnostic method in the study, given high sensitivity for both *Pf* and *Pv*  
533 species compared to microscopy and RDTs. Microscopy had reasonable sensitivity for *Pf* (84.3%), but  
534 poor sensitivity for *Pv* (39%). RDT had poor sensitivity for *Pf* (69.4%) and was almost completely  
535 unable to detect *Pv* (0.5%), suggesting little diagnostic utility in elimination. While the PCR method used  
536 was implementable from the reference lab supporting the field sites, the technical requirements and cost  
537 may render this approach challenging in some settings. Microscopy was able to detect gametocytes  
538 unlike the other two methods, providing additional insights into transmission potential. However,  
539 gametocyte detection is more labor intensive, requiring longer microscopy reads covering more fields.

540 A recent systematic review identified at least 10 randomized trials evaluating malaria MDA in  
541 high and low incidence settings [15]. In low-transmission settings using various regimens, both *Pf* and *Pv*  
542 burden were substantially reduced within 1-3 months. A prior systematic review of 32 studies from 2013  
543 found that MDA led to sustained malaria reductions only in geographically isolated communities [17]  
544 [32]. The key lesson from our study, and those preceding it, is the need for sustained intervention  
545 beyond three months, recognizing the difficulties comparing interventions from varied populations, risks

546 and settings [34]. Although impact is often relatively short-lived, pharmaceutically driven approaches to  
547 malaria elimination appear to be more effective in low intensity transmission settings such as Cambodia  
548 (1-10% prevalence). The most challenging elements to account for in any MDA study are movements in  
549 and out of clusters. The clusters on the Cambodian-Thai border in our study were not truly  
550 geographically isolated from malaria risk areas which tend to be occupational rather than residential.  
551 Despite these challenges, the present study sustained parasite-free intervals in MMP clusters longer than  
552 most prior efforts with 5 months before PCR-confirmed *Pf* reappeared in the study areas. Both  
553 approaches were safe with the MMP approach superior to FSAT for parasite reductions, potential to  
554 reduce resource requirements and scalability.

555 Cambodia has long been among the highest risk countries for antimalarial drug resistance for both  
556 *Pf* [35] and *Pv* [36]. Recent high rates of drug failure and tolerability considerations limited possible  
557 elimination regimens [4, 37]. Given a lack of options for treatment when the study was implemented, a  
558 monthly 3-day DP course was chosen as preferred chemoprophylaxis in the MMP clusters despite clinical  
559 DP failures widely reported in the study area three years before study start [38]. At the time of the study,  
560 Cambodia had recently replaced DP with A+M as first line *Pf* agent with a single 15mg dose of  
561 primaquine to prevent transmission. The recent drug policy change was based on inverse resistance  
562 patterns observed between DP and A+M in Northern Cambodia [35]. In line with these findings, there  
563 was a 32% initial DP failure rate in the MMP group in the first month, compared to no A+M regimen  
564 failures in the FSAT group, and only 3 A+M recrudescences over 6 months. However, all treatment  
565 failures in the MMP group were successfully cured using A+M rescue therapy on month 1 follow-up.  
566 While a ‘failing regimen’ ultimately managed to suppress *Pf* parasitemia there was a need to surveil for  
567 recrudescences. Despite initial DP treatment failures, from an elimination standpoint DP+PQ treatment in  
568 the MMP arm significantly outperformed FSAT using A+M treatment (RRR 60-70% for MMP compared  
569 to FSAT for cumulative *Pf* during the study period). Our study was not alone in selecting DP as a  
570 monthly blood stage elimination agent. The closest recent comparable study used monthly courses of DP  
571 with single low-dose PQ to eliminate *Pf* in Vietnam, Cambodia, Laos and Myanmar [39]. The study was

572 larger (~8,000 volunteers in 16 clusters) but coverage and acceptance were lower with fewer than half of  
573 those treated completing 3 months of therapy. Despite the limitations, the approach worked with *Pf*  
574 suppression persisting as long as one year in lower transmission areas. We did not find any significant  
575 drug resistance at the study sites and observed that 9 of 10 cases of highly resistant *PfPailin* strain were  
576 cured with initial therapy. To date there is limited evidence of a sustained MDA or prophylaxis approach  
577 generating significant resistance.

578 *Pv* will likely be the greatest long-term obstacle to malaria elimination in Cambodia and SE Asia  
579 [40]. *Pv* constituted 57% of overall malaria and 88% of malaria detected after initial enrollment in the  
580 present study. Blood-stage *Pv* prevalence at baseline was comparable to *Pf*, and previously reported  
581 relapse rates in the study area were as high as 70-80% in 2010 without primaquine radical cure [2]. Here,  
582 MMP effectively suppressed or eliminated blood-stage *Pv* during the three-month intervention period  
583 with zero detected cases of *Pv* through Month 3, despite higher baseline *Pv* prevalence in MMP clusters  
584 (8.4% compared to 2.7% in FSAT clusters). By contrast, monthly blood-stage *Pv* rates in the FSAT group  
585 remained largely unchanged between 2-4% throughout the study period. There are few studies of *Pv* anti-  
586 relapse therapy in elimination settings [41]. Interpretation is confounded by the complexity of  
587 distinguishing relapses, recrudescences, and reinfections [42]. In this study, it was impossible to  
588 determine whether MMP was effective against *Pv* because it cleared hypnozoites (PQ), interrupted  
589 transmission (PQ), reduced reinfection (DP or PQ), or simply suppressed apparent blood-stage relapses  
590 (DP). The results based on the timing of infection suggest that MMP *Pv* recurrences were more likely to  
591 be the result of relapses, while FSAT recurrences are more likely to be the result of reinfections  
592 (Supplemental Figure 2). The positive effect of ITU on *Pv* in FSAT supports the notion that ITU might  
593 have helped interrupt *Pv* transmission in those settings. Although a higher percentage of MMP cases were  
594 recurrences, there was an overall lower rate of *Pv* in the MMP group. The difference in interval between  
595 the two regimens may be due to a combination of factors – a higher reinfection rate of new *Pv* infections  
596 in FSAT, suppression of detectable relapse during the intervention period in MMP, or both. However, it

597 is clear that the FSAT approach had little effect on *Pv* rates despite prompt administration of primaquine  
598 radical cure following detection. This has implication for traditional malaria control programs, where  
599 even if radical cure treatment is administered by DOT, it may be difficult to reduce *Pv* malaria in an  
600 expeditious manner. Interpretation may be confounded by successive relapses of unrecognized  
601 subclinical disease, indicating a higher proportion of the population affected at baseline than detectable  
602 with current diagnostics.

603 A 22.5mg weekly primaquine dose was previously found to be effective in eliminating latent *Pv*  
604 in immigrants to Australia, and was the basis of the MMP regimen selected here [43]. *Pv* at enrollment  
605 was the single greatest predictor of *Pv* positivity during the study using logistic regression, suggesting  
606 that relapse played a major role in *Pv* infection rate. In both MMP and FSAT groups, approximately 30%  
607 of individuals positive for *Pv* at enrollment had a *Pv* recurrence during the study. This compared to a  
608 cumulative *Pv* rate of 7.4% in MMP and 15.6% in FSAT if *Pv* negative at enrollment. These findings  
609 suggest that regardless of the different PQ regimens used in MMP and FSAT, the cumulative 270 mg  
610 dose of PQ employed here [43] may not be completely effective at preventing relapse. This is in line with  
611 a recent study that found that PQ radical cure may only be 60-70% effective at preventing recurrences in  
612 this setting [44]. Relapse efficacy may also be affected by a high proportion of intermediate metabolizer  
613 genotypes for Cytochrome P450 2D6 polymorphisms [45]. Normal CYP2D6 activity is thought to be  
614 required for primaquine to be effective, though clinically significant reductions in primaquine  
615 effectiveness have not been conclusively demonstrated in Cambodia.

616 Malaria elimination efforts are unlikely to be successful without suitable attention paid to the  
617 infectious gametocyte. Treatment of blood stage parasites can stimulate gametocytemia and increase  
618 transmission risk [33]. Few agents are capable of effectively treating stage V gametocytes in the human  
619 host to block mosquito transmission. While artemisinins are thought to have some antigametocidal  
620 activity, PQ is the most effective drug for this purpose [46]. A single 45mg dose of PQ administered with  
621 blood-stage therapy was a highly effective transmission-blocking agent at similar geographical areas as  
622 the present elimination study [47], eliminating circulating *Pf* gametocytes. It also prevented transmission

623 from patient blood samples to laboratory reared mosquitoes compared to no primaquine therapy. A lower  
624 single 15mg dose is now widely recommended for transmission-blocking in combination with a blood  
625 stage agent. While the MMP and FSAT groups were treated with PQ, the MMP group received a weekly  
626 dose of PQ well in excess of the recommended transmission-blocking dose. The FSAT group received a  
627 single transmission-blocking dose only if confirmed *Pf* positive or a radical curative dose only if *Pv*  
628 positive, leaving subclinical gametocytemia untreated. In the MMP group, no microscopic *Pv*  
629 gametocytes were observed from Months 1-4 and no *Pf* gametocytes from Months 1 to 6. In the FSAT  
630 group, while no *Pf* gametocytes were observed from Months 2-6, *Pv* gametocytes were seen in 50-67% of  
631 FSAT *Pv* infections throughout the entire 6-month observation period, suggesting ongoing *Pv* transmission  
632 throughout the study. This may help explain why the addition of ITU was shown to be beneficial in  
633 FSAT where transmission was never interrupted with the drug therapies alone. While gametocytemia was  
634 not measured by PCR in the present study, microscopic gametocytemia is thought to have substantially  
635 higher transmission risk than sub-microscopic gametocytemia [48]. Unfortunately, assessing community-  
636 level impact of transmission blocking agents is extremely challenging [46]. Further, though clusters were  
637 geographically isolated by domicile, they were not necessarily isolated in the higher-risk occupational  
638 areas. In Cambodia, risks are largely occupational – forested areas patrolled by military personnel in this  
639 case [49]. Individuals may have been exposed to infectious bites outside their dwelling clusters, and may  
640 have transmitted disease there as well. As such we can only speculate on the relative contribution of  
641 transmission blocking effects to the results.

642 One of the key features distinguishing the study from prior attempts at MDA was our intent to  
643 determine effectiveness of chemoprophylaxis in the military in the MMP group as a potential elimination  
644 approach, in combination with vector interventions (ITUs). This MDA approach is often considered to be  
645 ineffective given risks for adverse events and drug resistance pressure on the parasite [15]. However,  
646 some have argued for targeted chemoprophylaxis in forested malaria-endemic areas [49]. The results  
647 here largely support that recommendation, suggesting that safe, effective chemoprophylaxis including an  
648 8-aminoquinoline is warranted in this low-transmission, high antimalarial drug resistance setting. A

649 combination of monthly 3-day treatment courses of DP and weekly low-dose PQ safely led to a Relative  
650 Risk Reduction of 100% over three months and 47% over six months. While it is impossible to assess the  
651 individual contribution of DP and PQ in this study, inferences can be made based on known mechanisms  
652 of action. The primary blood-stage post-treatment prophylactic effect was likely due to piperazine,  
653 despite substantial documentation of both clinical artemisinin and piperazine resistance in this area [4].  
654 While the DP combination initially failed to treat blood-stage disease in >30% of subjects, it appeared  
655 sufficient to suppress submicroscopic blood-stage parasitemia during the remaining intervention period.  
656 PQ also has ‘causal’ liver-stage antimalarial activity against *Pf* and *Pv*, and there may have been some  
657 synergy between DP and PQ in suppressing blood and liver-stage parasitemia [49]. It is impossible to  
658 distinguish the potential contributions or synergy of primaquine given the combination approach  
659 employed. Others have found similar success with prophylaxis using more limited regimens. A  
660 comparison of a monthly treatment course of artemether-lumefantrine showed significant risk reductions  
661 compared to a multivitamin in forest-dwellers in Cambodia [50]. The large number of variables in the  
662 study obviated establishing a control group for each of the interventions employed.

663 The study demonstrated the safety and tolerability of the pharmacologic approach to elimination.  
664 High compliance was likely achieved through the use of DOT administration. DP is known to be safe and  
665 well-tolerated with the exception of elevated risk of QT-interval prolongation when given in a  
666 compressed 2-day course [54]. The primary safety concern in the study was use of PQ in G6PD-deficient  
667 volunteers. We were the first group to employ the 22.5mg/week PQ dose regimen in an endemic area as  
668 an elimination tool to prevent *Pv* relapse. The 22.5mg weekly dose chosen for the MMP group was based  
669 on a previously safe, effective anti-relapse dose employed in Asian migrants to Australia [43]. PQ likely  
670 provided anti-gametocyte activity and at least some degree of ‘causal’ liver-stage prophylaxis. The FSAT  
671 groups used widely recommended PQ doses demonstrated to be safe in G6PD-deficiency for *Pf*  
672 transmission blocking and/or *Pv* anti-relapse. In the MMP group, 16% of volunteers were G6PD  
673 deficient, comparable to prior observations [55]. Only 15% of subjects had hemoglobin declines of >10%  
674 at day 3, none had declines of >25%, and none had to stop PQ treatment based on the pre-specified

675 individual halting rule of Grade 3 hemolysis. This is in line with expectations that even those with  
676 relatively severe G6PD deficiency are able to tolerate PQ in low doses [56] and the modified weekly  
677 regiment studied.

678         Vector-based interventions have long been a cornerstone of malaria control and containment.  
679 Insecticide-treated bed nets (ITN) have historically been responsible for large reductions in malaria in  
680 sub-Saharan Africa. However, ITNs are less effective in Southeast Asia with predominantly day-biting  
681 *Anopheles* species who breed in forested areas, and can be exophagic [49, 57]. Insecticide-treated  
682 clothing, typically using wash-resistant permethrin formulations, is often employed by military forces to  
683 reduce vector-borne disease risk. The vast majority of vector-based interventions are tested based on their  
684 efficacy against vector biting behavior. The study is also among the few to subject a vector-based  
685 intervention, particularly insecticide-treated uniforms and clothing to the rigor of a clinical trial of the  
686 disease of interest. Only a handful of studies to date have assessed disease outcomes [58], despite  
687 emerging concerns for malaria vector permethrin resistance in Africa [27]. Addition of insecticide-treated  
688 uniforms (ITU) reduced malaria prevalence when paired with the FSAT but not MMP approaches,  
689 suggesting this may be a good options for malaria elimination in select groups. Although difficult with  
690 multiple interventions simultaneously employed to definitively distinguish relative contributions to  
691 outcomes, the results support ITU use in regions with day-biting vectors. While clothing and uniforms  
692 were treated by the study team for this exercise, individual permethrin clothing treatment is relatively  
693 easy to perform. ITU use resulted in significantly lower *Pv* positivity rates ( $p < 0.01$ ) with RRR of ~60%  
694 for *Pv* compared to sITU. A similar effect size was seen for *Pf* with RRR of 40-60%. The latter  
695 difference was not statistically significant given the small number of *Pf* infections in the study. It is  
696 interesting to note that the observed effect size was consistent for both *Pf* and *Pv*. This was expected as  
697 the two species share the same vector and should be equally affected by vector control measures. No  
698 statistically significant difference was found in *Pf* and *Pv* infection rates for ITUs vs. sITUs in the MMP  
699 group. It is possible that chemoprophylactic effects of the MMP regimen may have masked added  
700 beneficial effects of uniform treatment.



701 This was the first study of a malaria elimination effort in the GMS carried out by and for a  
702 military population. The present study demonstrates the effectiveness of the approach described in our  
703 prior concept paper on malaria elimination by militaries in the GMS [28]. No elimination scheme can  
704 work without a well-trained team able to carry out the complex set of clinical and laboratory activities  
705 required. The joint team employed on this study included a large number of Royal Cambodian Armed  
706 Forces medical and logistics personnel. The study created a basic Unit of Action for malaria elimination  
707 easily replicated elsewhere. The Unit of Action included study physicians, nurses, lab technicians, data  
708 analysts and a large cadre of soldier-medics training and working alongside the multinational AFRIMS  
709 Malaria team. Achieving and sustaining the required operational tempo required for universal  
710 quantitative G6PD testing, frequent diagnostic PCR testing and DOT would not have been possible  
711 without significant RCAF support. The study demonstrated that elimination is not only possible within  
712 GMS militaries but can be achieved by GMS militaries supporting national efforts. Despite the  
713 achievement, those considering the approach must be mindful of the military ethical considerations, and  
714 implement appropriate safeguards such as the use of non-military personnel as ombudsmen during the  
715 consent process. Consent whether in the context of research or public health implementation, is essential  
716 to establish and maintain trust.

717 There were several limitations to the study. First, despite randomization, the multiplicity of  
718 simultaneous interventions makes it difficult to quantify relative contributions of individual interventions.  
719 This was a deliberate choice. The goal of the study was to combine what were thought to be the most  
720 regionally appropriate, safe, cost-effective elimination strategies available at the time rather than precisely  
721 delineate individual contributions of each intervention. Second, assessment of potential reinfection for *Pv*  
722 was challenging, given the difficulties in distinguishing relapse, reinfection and recrudescence. Third, we  
723 could not control for the effects of in- and out-migration. The former may have introduced additional  
724 disease burden to clusters while the latter caused losses to follow-up from occupational reassignment.  
725 Fourth, secular declines in parasite prevalence from either seasonal changes or ongoing control efforts in  
726 the region were also impossible to quantify. One or more no-intervention clusters may have helped



727 control for this, but were not undertaken for both ethical and practical considerations. To our knowledge,  
728 study sites selected did not undergo other control measures beyond those of the study during the  
729 observation period. Also, the study concluded during a time of the year generally considered to be a  
730 higher malaria transmission period. The enrollment began during low malaria transmission (January) and  
731 concluded during the rainy season (June) when malaria transmission in Cambodia typically increases  
732 [59]. Seasonality would likely have contributed to a secular rise, rather than fall, in infection rates over  
733 the course of the study if the control measures were ineffective. Finally, selection bias may have  
734 influenced cluster composition, though unavoidable for practical reasons. This was mitigated by site  
735 selection based on several years of prior malaria data provided by the RCAF. However, past rates cannot  
736 be relied on to predict actual transmission, and did not entirely do so here.

737

## 738 Conclusions

739 The all-encompassing approach to malaria elimination described here among mobile populations  
740 on the Cambodian-Thai border demonstrated that a chemoprophylaxis strategy (MMP) was more effective  
741 than a reactive-screen-and-treat approach (FSAT). However, FSAT intervention was improved by the  
742 addition of ITUs. The effects of MMP were longer lasting after the intervention was completed. This was  
743 true for both *Pf* and *Pv*, though in this area of MDR *Pf*, follow-up surveillance and retreatment were  
744 necessary for 30% of volunteers treated initially with DP. A weekly dose of 22.5mg primaquine was safe,  
745 well-tolerated, and appeared to potentiate DP prophylactic effects particularly against *Pv*. Individual  
746 contributions of weekly PQ could not be established. FSAT was not effective in reducing *Pv* prevalence.  
747 Insecticide-treated clothing appeared to provide additional benefit with the FSAT but not MMP approach.  
748 The MMP approach may be more easily scaled to eliminate malaria given reduced need for diagnostic  
749 assessments. The study informs a number of outstanding malaria elimination questions, and highlights  
750 regional militaries as a potent force for malaria elimination in the GMS.

751 The study provided valuable insights into the ongoing fight against malaria in Cambodia and  
752 underscores the importance of multifaceted approaches tailored to local epidemiology. Cambodia's  
753 National Malaria Program can make significant strides towards malaria elimination in the future by  
754 integrating community engagement and empowerment, targeted chemoprophylaxis, vector control  
755 monitoring and implementation of ITUs for military populations, and evaluation into a comprehensive,  
756 adaptive approach.

## 757 References

- 758 1. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM,  
759 Tun KM, van der Pluijm RW, et al: **The spread of artemisinin-resistant *Plasmodium falciparum***  
760 **in the Greater Mekong subregion: a molecular epidemiology observational study.** *Lancet Infect*  
761 *Dis* 2017, **17**:491-497.
- 762 2. Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, Gosi P, Lanteri C, Chaorattanakawee S,  
763 Sriwichai S, et al: **Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine**  
764 **for uncomplicated malaria in military personnel in northern Cambodia: an open-label**  
765 **randomized trial.** *PLoS One* 2014, **9**:e93138.
- 766 3. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in  
767 Cambodia 1 Study C: **Evidence of artemisinin-resistant malaria in western Cambodia.** *N Engl J*  
768 *Med* 2008, **359**:2619-2620.
- 769 4. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, Se Y, Chann S, Ittiverakul  
770 M, Sia-ngam P, et al: **Dihydroartemisinin-piperaquine failure associated with a triple mutant**  
771 **including kelch13 C580Y in Cambodia: an observational cohort study.** *Lancet Infect Dis* 2015,  
772 **15**:683-691.
- 773 5. Wongsrichanalai C, Meshnick SR: **Declining artesunate-mefloquine efficacy against falciparum**  
774 **malaria on the Cambodia-Thailand border.** *Emerg Infect Dis* 2008, **14**:716-719.
- 775 6. Phương VT: **New initiatives launched to end malaria in ASEAN.** In *Vietnam*. Hanoi,  
776 Vietnam2018.
- 777 7. **Countries in WHO South-East Asia Region renew commitment to eliminate malaria by 2030**  
778 [[https://www.who.int/southeastasia/news/detail/05-05-2022-countries-in-who-south-east-asia-](https://www.who.int/southeastasia/news/detail/05-05-2022-countries-in-who-south-east-asia-region-renew-commitment-to-eliminate-malaria-by-2030)  
779 [region-renew-commitment-to-eliminate-malaria-by-2030](https://www.who.int/southeastasia/news/detail/05-05-2022-countries-in-who-south-east-asia-region-renew-commitment-to-eliminate-malaria-by-2030)]
- 780 8. Sovannaroeth S, Ngor P, Khy V, Dunn JC, Burbach MK, Peng S, Mak S, Siv K, Manzoni G, Guintran  
781 JO, et al: **Accelerating malaria elimination in Cambodia: an intensified approach for targeting**  
782 **at-risk populations.** *Malar J* 2022, **21**:209.
- 783 9. Smith C, Whittaker M: **Beyond mobile populations: a critical review of the literature on malaria**  
784 **and population mobility and suggestions for future directions.** *Malar J* 2014, **13**:307.
- 785 10. Bhumiratana A, Intarapuk A, Sorosjinda-Nunthawarasilp P, Maneekan P, Koyadun S: **Border**  
786 **malaria associated with multidrug resistance on Thailand-Myanmar and Thailand-Cambodia**  
787 **borders: transmission dynamic, vulnerability, and surveillance.** *Biomed Res Int* 2013,  
788 **2013**:363417.

- 789 11. Wangroongsarb P, Sudathip P, Satimai W: **Characteristics and malaria prevalence of migrant**  
790 **populations in malaria-endemic areas along the Thai-Cambodian border.** *Southeast Asian J*  
791 *Trop Med Public Health* 2012, **43**:261-269.
- 792 12. Bustos MD, Wongsrichanalai C, Delacollette C, Burkholder B: **Monitoring antimalarial drug**  
793 **efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.**  
794 *Southeast Asian J Trop Med Public Health* 2013, **44 Suppl 1**:201-230; discussion 306-207.
- 795 13. Delacollette C, D'Souza C, Christophel E, Thimasarn K, Abdur R, Bell D, Dai TC, Gopinath D, Lu S,  
796 Mendoza R, et al: **Malaria trends and challenges in the Greater Mekong Subregion.** *Southeast*  
797 *Asian J Trop Med Public Health* 2009, **40**:674-691.
- 798 14. Nofal SD, Peto TJ, Adhikari B, Tripura R, Callery J, Bui TM, von Seidlein L, Pell C: **How can**  
799 **interventions that target forest-goers be tailored to accelerate malaria elimination in the**  
800 **Greater Mekong Subregion? A systematic review of the qualitative literature.** *Malar J* 2019,  
801 **18**:32.
- 802 15. Schneider ZD, Shah MP, Boily MC, Busbee AL, Hwang J, Lindblade KA, Gutman JR: **Mass Drug**  
803 **Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis.** *Am J*  
804 *Trop Med Hyg* 2023.
- 805 16. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J: **Mass drug administration for**  
806 **malaria.** *Cochrane Database Syst Rev* 2013, **2013**:CD008846.
- 807 17. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, Shanks GD, Slutsker L, Kachur  
808 SP, Wegbreit J, et al: **Review of mass drug administration for malaria and its operational**  
809 **challenges.** *Am J Trop Med Hyg* 2015, **93**:125-134.
- 810 18. Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP: **Mass primaquine**  
811 **treatment to eliminate vivax malaria: lessons from the past.** *Malar J* 2014, **13**:51.
- 812 19. Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, Penny MA, Gerardin J,  
813 White LJ, Chitnis N, et al: **Role of mass drug administration in elimination of Plasmodium**  
814 **falciparum malaria: a consensus modelling study.** *Lancet Glob Health* 2017, **5**:e680-e687.
- 815 20. Searle KM, Hamapumbu H, Lubinda J, Shields TM, Pinchoff J, Kobayashi T, Stevenson JC, Bridges  
816 DJ, Larsen DA, Thuma PE, et al: **Evaluation of the operational challenges in implementing**  
817 **reactive screen-and-treat and implications of reactive case detection strategies for malaria**  
818 **elimination in a region of low transmission in southern Zambia.** *Malar J* 2016, **15**:412.
- 819 21. Newby G, Cotter C, Roh ME, Harvard K, Bennett A, Hwang J, Chitnis N, Fine S, Stresman G, Chen  
820 I, et al: **Testing and treatment for malaria elimination: a systematic review.** *Malar J* 2023,  
821 **22**:254.
- 822 22. Sanann N, Peto TJ, Tripura R, Callery JJ, Nguon C, Bui TM, Nofal SD, von Seidlein L, Lek D,  
823 Dondorp AM, et al: **Forest work and its implications for malaria elimination: a qualitative**  
824 **study.** *Malar J* 2019, **18**:376.
- 825 23. Cook J, Xu W, Msellem M, Vonk M, Bergstrom B, Gosling R, Al-Mafazy AW, McElroy P, Molteni F,  
826 Abass AK, et al: **Mass screening and treatment on the basis of results of a Plasmodium**  
827 **falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar.** *J Infect*  
828 *Dis* 2015, **211**:1476-1483.
- 829 24. Kern SE, Tiono AB, Makanga M, Gbadoe AD, Premji Z, Gaye O, Sagara I, Ubben D, Cousin M,  
830 Oladiran F, et al: **Community screening and treatment of asymptomatic carriers of Plasmodium**  
831 **falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and**  
832 **simulation analysis.** *Malar J* 2011, **10**:210.
- 833 25. Scott CA, Yeshiwondim AK, Serda B, Guinovart C, Tesfay BH, Agmas A, Zeleke MT, Guesses GS,  
834 Ayenew AL, Workie WM, et al: **Mass testing and treatment for malaria in low transmission**  
835 **areas in Amhara Region, Ethiopia.** *Malar J* 2016, **15**:305.

- 836 26. Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, Boum Y, 2nd, Brito M, Charoenkwan P,  
837 Clements A, et al: **Correction: Quantification of glucose-6-phosphate dehydrogenase activity**  
838 **by spectrophotometry: A systematic review and meta-analysis.** *PLoS Med* 2020, **17**:e1003311.
- 839 27. Yusuf MA, Oshaghi MA, Vatandoost H, Hanafi-Bojd AA, Enayati A, Jalo RI, Aminu A, Daneji IM:  
840 **Current Status of Insecticide Susceptibility in the Principal Malaria Vector, *Anopheles gambiae***  
841 **in Three Northern States of Nigeria.** *J Arthropod Borne Dis* 2021, **15**:196-206.
- 842 28. Manning JE, Satharath P, Gaywee J, Lopez MN, Lon C, Saunders DL: **Fighting the good fight: the**  
843 **role of militaries in malaria elimination in Southeast Asia.** *Trends Parasitol* 2014, **30**:571-581.
- 844 29. Manning J, Lon C, Spring M, Wojnarski M, Somethy S, Chann S, Gosi P, Soveasna K, Sriwichai S,  
845 Kuntawunginn W, et al: **Cluster-randomized trial of monthly malaria prophylaxis versus**  
846 **focused screening and treatment: a study protocol to define malaria elimination strategies in**  
847 **Cambodia.** *Trials* 2018, **19**:558.
- 848 30. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, Viriyakosol S: **Biased distribution**  
849 **of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand.** *Trans R*  
850 *Soc Trop Med Hyg* 1999, **93**:369-374.
- 851 31. Campbell MK, Thomson S, Ramsay CR, MacLennan GS, Grimshaw JM: **Sample size calculator for**  
852 **cluster randomized trials.** *Comput Biol Med* 2004, **34**:113-125.
- 853 32. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, Chowwiwat N, Raksapraidee R,  
854 Wilairisak P, Phyo AP, et al: **Haemolysis in G6PD Heterozygous Females Treated with**  
855 **Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative**  
856 **Regimens.** *PLoS Med* 2017, **14**:e1002224.
- 857 33. Mason DP, McKenzie FE: **Blood-stage dynamics and clinical implications of mixed Plasmodium**  
858 **vivax-Plasmodium falciparum infections.** *Am J Trop Med Hyg* 1999, **61**:367-374.
- 859 34. Kagaya W, Gitaka J, Chan CW, Kongere J, Md Idris Z, Deng C, Kaneko A: **Malaria resurgence after**  
860 **significant reduction by mass drug administration on Ngodhe Island, Kenya.** *Sci Rep* 2019,  
861 **9**:19060.
- 862 35. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, Saingam P,  
863 Buathong N, Sriwichai S, Chann S, et al: **Ex Vivo Drug Susceptibility Testing and Molecular**  
864 **Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest**  
865 **Emerging Piperaquine Resistance.** *Antimicrob Agents Chemother* 2015, **59**:4631-4643.
- 866 36. Chaorattanakawee S, Lon C, Chann S, Thay KH, Kong N, You Y, Sundrakes S, Thamnurak C,  
867 Chattrakarn S, Praditpol C, et al: **Measuring ex vivo drug susceptibility in Plasmodium vivax**  
868 **isolates from Cambodia.** *Malar J* 2017, **16**:392.
- 869 37. Wojnarski M, Lon C, Vanachayangkul P, Gosi P, Sok S, Rachmat A, Harrison D, Berjohn CM,  
870 Spring M, Chaoratanakawee S, et al: **Atovaquone-Proguanil in Combination With Artesunate to**  
871 **Treat Multidrug-Resistant P. falciparum Malaria in Cambodia: An Open-Label Randomized**  
872 **Trial.** *Open Forum Infect Dis* 2019, **6**:ofz314.
- 873 38. Saunders DL, Vanachayangkul P, Lon C, Program USAMMR, National Center for Parasitology E,  
874 Malaria C, Royal Cambodian Armed F: **Dihydroartemisinin-piperaquine failure in Cambodia.** *N*  
875 *Engl J Med* 2014, **371**:484-485.
- 876 39. von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, Pongvongsa T, Lwin KM,  
877 Keerecharoen L, Kajeewiwa L, et al: **The impact of targeted malaria elimination with mass**  
878 **drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.** *PLoS*  
879 *Med* 2019, **16**:e1002745.
- 880 40. Siv S, Roca-Feltrer A, Vinjamuri SB, Bouth DM, Lek D, Rashid MA, By NP, Popovici J, Huy R,  
881 Menard D: **Plasmodium vivax Malaria in Cambodia.** *Am J Trop Med Hyg* 2016, **95**:97-107.
- 882 41. Shah MP, Westercamp N, Lindblade KA, Hwang J: **Mass Relapse Prevention to Reduce**  
883 **Transmission of Plasmodium vivax-A Systematic Review.** *Am J Trop Med Hyg* 2023.

- 884 42. Lin JT, Hathaway NJ, Saunders DL, Lon C, Balasubramanian S, Kharabora O, Gosi P, Sriwichai S,  
885 Kartchner L, Chuor CM, et al: **Using Amplicon Deep Sequencing to Detect Genetic Signatures of**  
886 **Plasmodium vivax Relapse.** *J Infect Dis* 2015, **212**:999-1008.
- 887 43. Grimmond TR, Cameron AS: **Primaquine-chloroquine prophylaxis against malaria in Southeast-**  
888 **Asian refugees entering South Australia.** *Med J Aust* 1984, **140**:322-325.
- 889 44. Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, Villegas MF, Val F,  
890 Monteiro WM, Brito MAM, et al: **Tafenoquine versus Primaquine to Prevent Relapse of**  
891 **Plasmodium vivax Malaria.** *N Engl J Med* 2019, **380**:229-241.
- 892 45. Spring MD, Lon C, Sok S, Sea D, Wojnarski M, Chann S, Kuntawunginn W, Kheang Heng T, Nou S,  
893 Arsanok M, et al: **Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of**  
894 **Cambodians at High Risk for Infections with Plasmodium vivax.** *Am J Trop Med Hyg* 2020,  
895 **103**:756-759.
- 896 46. Delves MJ, Angrisano F, Blagborough AM: **Antimalarial Transmission-Blocking Interventions:**  
897 **Past, Present, and Future.** *Trends Parasitol* 2018, **34**:735-746.
- 898 47. Lin JT, Lon C, Spring MD, Sok S, Chann S, Ittiverakul M, Kuntawunginn W, My M, Thay K, Rahman  
899 R, et al: **Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum**  
900 **transmission in Cambodia: An open-label randomized trial.** *PLoS One* 2017, **12**:e0168702.
- 901 48. Lin JT, Saunders DL, Meshnick SR: **The role of submicroscopic parasitemia in malaria**  
902 **transmission: what is the evidence?** *Trends Parasitol* 2014, **30**:183-190.
- 903 49. von Seidlein L, Peto TJ, Tripura R, Pell C, Yeung S, Kindermans JM, Dondorp A, Maude R: **Novel**  
904 **Approaches to Control Malaria in Forested Areas of Southeast Asia.** *Trends Parasitol* 2019,  
905 **35**:388-398.
- 906 50. Tripura R, von Seidlein L, Sovannaroth S, Peto TJ, Callery JJ, Sokha M, Ean M, Heng C, Conradis-  
907 Jansen F, Madmanee W, et al: **Antimalarial chemoprophylaxis for forest goers in southeast**  
908 **Asia: an open-label, individually randomised controlled trial.** *Lancet Infect Dis* 2023, **23**:81-90.
- 909 51. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, Lebouilleux D,  
910 Njuguna P, Peshu N, et al: **Four-year efficacy of RTS,S/AS01E and its interaction with malaria**  
911 **exposure.** *N Engl J Med* 2013, **368**:1111-1120.
- 912 52. Datoo MS, Dicko A, Tinto H, Ouedraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F,  
913 Natama HM, Weston S, et al: **Safety and efficacy of malaria vaccine candidate R21/Matrix-M in**  
914 **African children: a multicentre, double-blind, randomised, phase 3 trial.** *Lancet* 2024, **403**:533-  
915 544.
- 916 53. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, et  
917 al: **Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia:**  
918 **primaquine, mass drug administration and artemisinin resistance.** *PLoS One* 2012, **7**:e37166.
- 919 54. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, Se Y, Somethy S, Phann ST, Chann S,  
920 et al: **Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of**  
921 **dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged**  
922 **corrected QT interval.** *Antimicrob Agents Chemother* 2014, **58**:6056-6067.
- 923 55. Wojnarski B, Lon C, Sea D, Sok S, Sriwichai S, Chann S, Hom S, Boonchan T, Ly S, Sok C, et al:  
924 **Evaluation of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test**  
925 **in the field settings and assessment of perceived risk from primaquine at the community level**  
926 **in Cambodia.** *PLoS One* 2020, **15**:e0228207.
- 927 56. White NJ: **Primaquine to prevent transmission of falciparum malaria.** *Lancet Infect Dis* 2013,  
928 **13**:175-181.
- 929 57. Cheng B, Htoo SN, Mhote NPP, Davison CM: **A systematic review of factors influencing**  
930 **participation in two types of malaria prevention intervention in Southeast Asia.** *Malar J* 2021,  
931 **20**:195.



- 932 58. Soto J, Medina F, Dember N, Berman J: **Efficacy of permethrin-impregnated uniforms in the**  
933 **prevention of malaria and leishmaniasis in Colombian soldiers.** *Clin Infect Dis* 1995, **21**:599-  
934 602.
- 935 59. Chhim S, Piola P, Housen T, Herbreteau V, Tol B: **Malaria in Cambodia: A Retrospective Analysis**  
936 **of a Changing Epidemiology 2006-2019.** *Int J Environ Res Public Health* 2021, **18**.

937

938

939

## 940 Acknowledgements

941 We are grateful to the study participants and communities who participated in and supported this study.  
942 We also thank the Royal Cambodian Armed Forces for their support.

### 943 **Disclaimer**

944 The views expressed in this article are those of the authors and do not reflect the official policy of the US  
945 Department of the Army, US Department of Defense, the US Government or the Royal Government of  
946 Cambodia.

### 947 **Author contributions**

948 Study design: DLS, JEM, PS, JTL, SS, WK, PG

949 Data collection: All

950 Data analysis: MW, SC, TB, SS, PG, DLS, WK, TK, PG

951 Data interpretation and study conclusions: TB, MW, SC, SS, PG, JTL, DLS, JEM, MS, PV

952 Writing manuscript: MW, DLS, SC,

953 Editing manuscript: DLS, SC, SS, JEM, JTL, MS

954 All authors read and approved the final manuscript.

### 955 **Funding**

956 The study was supported by a grant from the Bill and Melinda Gates Foundation and the Defense  
957 Malaria Assistance Program. The funding source played no role in the drafting, review or approval of the  
958 manuscript.

### 959 **Availability of data and materials**

960 The dataset supporting the conclusions of this article is included within the article and its additional files.

### 961 **Declarations**

962 *Ethics approval and consent to participate*

963 This study was approved by the Institutional Review Board at the Walter Reed Army Institute of  
964 Research and the Cambodian National Ethics Committee on Human Research. All study participants  
965 provided written study consent to participate.

966 *Consent for publication*

967 All study subjects agreed to publication of the study results in the medical literature without their  
968 identity at consent prior to participation.

969 *Competing interests*

970 The authors declare that they have no competing interests.

971 Supplemental Material

972

Time	MMP W	MMP LTF	MMP ToT	MMP %	FSAT W	FSAT LTF	FSAT ToT	FSAT %	TOT W	TOT LTF	TOT	ToT %
D1-30	7	1	8	1.5%	5	1	6	1.2%	12	2	14	1.3%
D31-60	12	0	12	2.2%	11	4	15	2.9%	23	4	27	2.6%
D61-90	4	1	5	0.9%	9	8	17	3.3%	13	9	22	2.1%
D91-180	19	6	25	4.7%	25	12	37	7.2%	44	18	62	5.9%
Total	42	8	50	9.3%	50	25	75	14.5%	92	33	125	11.9%

973

974 **Supplemental Table 1.** Withdrawals (W) and losses to follow-up (LTF) over time by treatment group  
975 and total volunteers (TOT).  
976

	<i>Pf</i> - high endemicity			95% C.I.		Odds-Ratio	95% C.I.		p-value
	Total	<i>Pf</i> Positive	Percent	lower	upper		lower	upper	
FSAT.sITU	97	8	8.2%	3.6%	15.6%	<i>Reference</i>			
FSAT.ITU	105	4	3.8%	1.1%	9.5%	0.464	0.135	1.593	n.s.
MMP.sITU	107	5	4.7%	1.5%	10.6%	0.545	0.172	1.727	n.s.
MMP.ITU	106	0	0.0%	0.0%	3.4%	-	-	-	-

	<i>Pv</i> - high endemicity			95% C.I.		Odds-Ratio	95% C.I.		p-value
	Total	<i>Pv</i> Positive	Percent	lower	upper		lower	upper	
FSAT.sITU	113	30	26.5%	18.7%	35.7%	<i>Reference</i>			
FSAT.ITU	105	12	11.4%	6.1%	19.1%	0.357	0.172	0.742	0.0056
MMP.sITU	115	12	10.4%	5.5%	17.5%	0.322	0.155	0.668	0.0023
MMP.ITU	108	10	9.3%	4.5%	16.4%	0.282	0.13	0.612	0.0013

	<i>Pv</i> - low endemicity			95% C.I.		Odds-Ratio	95% C.I.		p-value
	Total	<i>Pv</i> Positive	Percent	lower	upper		lower	upper	
FSAT.sITU	122	12	9.8%	5.2%	16.6%	<i>Reference</i>			
FSAT.ITU	93	4	4.3%	1.2%	10.7%	0.444	0.137	1.44	n.s.
MMP.sITU	106	2	1.9%	0.2%	6.7%	0.192	0.042	0.889	n.s.
MMP.ITU	111	8	7.2%	3.2%	13.7%	0.777	0.301	2.01	n.s.


977

978 **Supplemental Table 2. Summary logistic regression analysis results.** All comparisons are made with respect to  
979 FSAT randomized to sham-treated uniforms (FSAT+sITU). In high *Pf*-endemicity clusters, both FSAT with treated  
980 uniforms and MMP with untreated uniforms had 2-fold less risk for malaria infection (ns). In high *Pv* endemicity  
981 clusters, FSAT with treated uniforms or MMP with or without treated uniforms had a roughly 3-fold significant  
982 decrease (95% CI of 1.5-fold to 6.5-fold) in malaria risk ( $p < 0.01$ ). There was a trend toward decrease in *Pv* risk in  
983 low endemicity clusters associated with treated uniforms or MMP (ns).  
984  
985



986 Recurrent *Pv* infection during study follow-up

987 Nearly all cases of malaria recurrence (26/30, 86%) after the first monthly follow-up were due to  
 988 *Pv* malaria (Fig 3C and D). There were 13 *Pv* recurrences in FSAT treatment group and 13 cases in  
 989 MMP. These *Pv* recurrences may represent relapses or new infections. Logistic regression revealed that  
 990 recurrence of *Pv* in MMP was associated with diagnosis of *Pv* on enrollment ( $p < 0.001$ ) and lower weekly  
 991 PQ dose ( $< 5\text{mg/kg/total dose}$ ;  $p < 0.001$ ). Among the volunteers with at least one episode of *Pv* malaria,  
 992 the cumulative risk of *Pv* recurrence (Kaplan-Meier analysis) was 8% in MMP arm and 17% in FSAT  
 993 within 150 days of follow up (Supplemental Figure 1A). There were three notable distinctions between  
 994 *Pv* recurrences in the MMP and FSAT treatment groups. First, in the MMP group, 100% (13/13) of cases  
 995 of *Pv* recurrence were in individuals that tested positive for *Pv* at enrollment which was significantly  
 996 higher than the 31% (4/13) of cases in FSAT ( $p < 0.001$ ). Second, in the FSAT treatment group, subjects  
 997 wearing sITUs were approximately three times as likely to experience a *Pv* recurrence compared to  
 998 subjects wearing ITUs ( $p < 0.01$ ), while in the MMP group there was no significant difference with  
 999 respect to uniform. Third, the mean interval between the first and second *Pv* infection was significantly  
 1000 longer for MMP, at 166 days (s.d. 23 days) than for FSAT, at 108 days (s.d. 31 days) ( $p < 10^{-4}$ )



1001  
 1002 **Supplemental Figure 1. Recurrent *Pv* infections in subjects with at least one *Pv* infection.** A) Survival curve to  
 1003 a second *Pv* infection from the first *Pv* infection for all subjects with at least one documented *Pv* infection in the  
 1004 FSAT (red) and MMP (blue) treatment groups. B) Time interval between observing the first and second *Pv* infection  
 1005 for all subjects that had two documented *Pv* infections in the study. MMP (blue) and FSAT (red) treatment groups  
 1006 are shown as well sITU (open symbol) and ITU (closed symbol).